{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:44:32Z","timestamp":1788799472980,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2005,10,7]],"date-time":"2005-10-07T00:00:00Z","timestamp":1128643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T\u2010cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (<jats:italic>n<\/jats:italic> = 26 patients); peripheral T\u2010cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (<jats:italic>n<\/jats:italic> = 5 patients); and Sezary syndrome (SS) (<jats:italic>n<\/jats:italic> = 1 patient) were enrolled in a 7\u2010institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28\u2010day schedule at a dose of 1200 mg\/m<jats:sup>2<\/jats:sup> intravenously over 30 minutes for a total of 6 cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4\u201322 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea\/emesis or organ toxicity was noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21449","type":"journal-article","created":{"date-parts":[[2005,10,7]],"date-time":"2005-10-07T14:46:36Z","timestamp":1128696396000},"page":"2437-2441","source":"Crossref","is-referenced-by-count":141,"title":["Gemcitabine as frontline treatment for cutaneous T\u2010cell lymphoma"],"prefix":"10.1002","volume":"104","author":[{"given":"Enrica","family":"Marchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Bernengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,10,7]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze R","year":"1997","journal-title":"Blood."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.45"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203030-00006"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2003.12.003"},{"key":"e_1_2_5_7_2","first-page":"167","article-title":"Immunotoxin DAB389\u2010Interleukin 2 (ONTAK) in the management of cutaneuous T\u2010cell lymphoma","volume":"2","author":"Duvic M","year":"1999","journal-title":"Curr Pract Med."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb52680.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11593"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90007-0"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2603"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008409601731"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01139.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"key":"e_1_2_5_17_2","first-page":"926","article-title":"Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients","volume":"85","author":"Zinzani PL","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3786"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02795.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X"},{"key":"e_1_2_5_21_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050368"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008377724139"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3117"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04226.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077995"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.009"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:54:44Z","timestamp":1760306084000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21449"}},"subtitle":["Phase II study of 32 patients"],"short-title":[],"issued":{"date-parts":[[2005,10,7]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1002\/cncr.21449"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21449","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,7]]}}}